SciSparc Ltd. (NASDAQ:SPRC – Get Free Report) was the target of a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 10,052 shares, a decrease of 61.4% from the June 30th total of 26,064 shares. Based on an average daily trading volume, of 42,754 shares, the days-to-cover ratio is currently 0.2 days. Approximately 1.8% of the shares of the stock are short sold.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on SPRC. Weiss Ratings reiterated a “sell (e+)” rating on shares of SciSparc in a research report on Tuesday, May 26th. Wall Street Zen raised shares of SciSparc to a “hold” rating in a report on Saturday, July 18th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, SciSparc presently has an average rating of “Sell”.
Read Our Latest Research Report on SPRC
SciSparc Stock Up 2.1%
SciSparc (NASDAQ:SPRC – Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The company reported ($31.60) EPS for the quarter. The firm had revenue of $0.20 million during the quarter.
SciSparc Company Profile
SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.
The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.
Featured Articles
- Five stocks we like better than SciSparc
- 3 Stocks Standing Out and 2 Losing Momentum as the Tech Rally Cracks
- 5 AI Stocks Are Pulling Back—Which Growth Catalysts Still Look Strongest?
- Middleby Is Betting a Leaner Business Can Unlock More Value
- 3 Value ETFs to Consider as Growth Stocks Lag Behind
Receive News & Ratings for SciSparc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciSparc and related companies with MarketBeat.com's FREE daily email newsletter.
